Immunotherapy Candidate CV-301 Shows Promise in Colorectal Cancer
Treated patients have significantly better survival versus matched controls (May 29)
Promising data have been reported from a phase II trial of the cancer immunotherapy candidate CV-301 (Bavarian Nordic) in patients with resected metastatic colorectal cancer. The new findings were published in the Annals of Surgery.
In a study conducted at Duke University, 74 patients who were disease-free after surgical resection of metastatic colon cancer received chemotherapy followed by immunotherapy with CV-301 (formerly PANVAC-VF), either as CV-301–modified dendritic cells or in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). The overall survival of the CV-301–treated patients was significantly longer (P < 0.0001) compared with that of control patients, who were matched for key clinical features and had similar surgery and chemotherapy. Treatment with CV-301 was well tolerated, with injection-site reactions, fever, fatigue, and muscle soreness as the most common side effects.
CV-301 (CEA-MUC-1-TRICOM) is an immunotherapy candidate for the treatment of multiple cancers. It originates from the same poxvirus platform as Prostvac (Bavarian Nordic), a therapeutic cancer vaccine in phase III clinical development.
Both CV-301 and Prostvac are prime-boost vaccines that combine two different poxviruses (vaccinia and fowlpox). Collectively, these two product candidates, along with earlier generations of these vaccines, have been the subject of more than 30 clinical trials involving more than 1,100 patients with prostate, breast, lung, colorectal, gastric, pancreatic, ovarian, and other cancers.
While Prostvac incorporates a single antigen that is over-expressed in prostate cancer (prostate-specific antigen [PSA]), CV-301 incorporates two antigens (carcinoembryonic antigen [CEA] and epithelial tumor antigen MUC-1), which are over-expressed in other major cancers, including breast and colon cancers.
Source: Bavarian Nordic; May 29, 2013.